Rates of anti-tuberculosis drug resistance in kampala- Uganda are low and not associated with HIV infection

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Lukoye, Deus ^a,c   Cobelens, Frank G J ^b   Ezati, Nicholas ^c   Kirimunda, Samuel ^d   Adatu, Francis E ^c   Lule, Joseph K ^e   Nuwaha, Fred ^e   Joloba, Moses L ^c,d  

^a Makerere College of Health Sciences   (Uganda)

^b AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^c Makerere University College of Health Sciences ^*

^d MAKERERE UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Uganda)

^e MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH CARE; HEALTH CARE PERSONNEL; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; SPUTUM SMEAR; TUBERCULOSIS; UGANDA; DISEASE TRANSMISSION; INCIDENCE; MULTIDRUG RESISTANT TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HEALTH PERSONNEL; HIV INFECTIONS; HUMANS; INCIDENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; UGANDA;

EID: 79251548542     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016130     Document Type: Article

References (14)

1. WHO/IUATLD WIT (2004) Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Geneva Third Global Report.
2. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, et al. (2009) Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373: 1861-1873.
3. WHO (2008) Anti-tuberculosis drug resistance in the world 4th global report. Geneva WHO/HTM/TB. Pp 394.
4. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, et al. (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368: 1575-1580.
5. Suchindran S, Brouwer ES, Van Rie A (2009) Is HIV Infection a Risk Factor for Multi-Drug Resistant Tuberculosis? A Systematic Review. PLoS ONE 4: e5561.
6. Ammassari (2001) Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 26: 326-331.
7. Bretzel G, Aziz M, Wendl-Richter U, Adatu F, Aisu T, et al. (1999) Antituberculosis drug resistance surveillance in Uganda 1996-1997. Int J Tuberc Lung Dis 3: 810-815.
8. Temple B, Ayakaka I, Ogwang S, Nabanjja H, Kayes S, et al. (2008) Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis 47: 1126-1134.
9. WHO (2003) Global Project On Anti-Tuberculosis Drug Resistance Surveillance, Guidelines For Surveillance of Drug Resistant Tuberculosis GENEVA 2ND Ed.
10. WHO (2001) Guidelines for susceptibility testing for second-line antituberculosis drugs for DOTS-Plus. Geneva Switzerland. WHO.
11. Chonde TM, Basra D, Mfinanga SG, Range N, Lwilla F, et al. (2010) National anti-tuberculosis drug resistance study in Tanzania. Int J Tuberc Lung Dis 14: 967-972.
12. Umubyeyi AN, Vandebriel G, Gasana M, Basinga P, Zawadi JP, et al. (2007) Results of a national survey on drug resistance among pulmonary tuberculosis patients in Rwanda. Int J Tuberc Lung Dis 11: 189-194.
13. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, et al. (2007) HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 196 (Suppl 1): S86-107.
14. Menzies D BA, Paydar A, Royce S, Madhukar P, Burman W, et al. (2009) Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PloS Med 6: 1000150.